Challenging the Dogma: NAD+ and the Reversal of Advanced Alzheimer’s Disease

For over a century, Alzheimer’s disease (AD) has been viewed as a one-way street: a progressive, irreversible decline of the human brain. However, a groundbreaking study published in Cell Reports Medicine by Chaubey et al. (2026) provides a "proof of principle" that advanced AD-like pathology and cognitive deficits can be pharmacologically reversed. By focusing on a vital molecule called nicotinamide adenine dinucleotide (NAD+), researchers successfully restored cognitive function in mice with severe, late-stage disease.

The Study: Restoring Brain Resilience

The research team investigated whether AD is driven by a fundamental loss of "brain resilience", which is the organ’s intrinsic ability to repair itself and resist damage. They identified the disruption of NAD+ homeostasis (the balance of NAD+ levels) as a central mechanism in this loss of resilience.

The Methodology

The researchers utilized two distinct mouse models to represent the different drivers of human AD:

• 5xFAD mice: A model of amyloid-beta (Aβ) plaque accumulation.

• PS19 mice: A model of tau protein tangles.

Crucially, they initiated treatment at "advanced-disease stages" 11 months for PS19 mice (near their 12-month lifespan) and 6 months for 5xFAD mice, after cognitive deficits and pathology were already well-established.

The Treatment: P7C3-A20

The study centered on a neuroprotective compound called P7C3-A20, which restores NAD+ to its natural, healthy balance without exceeding normal limits.

Key Findings: Reversing the "Irreversible"

The results were comprehensive, showing that restoring NAD+ balance could essentially "reboot" a failing brain.

1. Full Cognitive Recovery

In mice that were already symptomatic and cognitively impaired, treatment with P7C3-A20 resulted in full recovery of learning and memory. This was demonstrated across multiple behavioral tests, including

• Novel Object Recognition: Restoring the ability to remember familiar items.

• Morris Water Maze: Recovering spatial learning and navigation.

• Rotarod: Reversing motor coordination and learning deficits.

2. Repairing the Infrastructure

The drug did more than just improve behavior; it repaired the physical damage of the disease:

• Blood-Brain Barrier (BBB): Advanced AD causes the "leaking" of the BBB. P7C3-A20 reversed this deterioration and protected the delicate microvascular cells that keep toxins out of the brain.

• Neuroinflammation and Stress: The treatment reversed tau phosphorylation, DNA damage, oxidative stress, and chronic neuroinflammation.

• Brain Plasticity: It enhanced hippocampal neurogenesis (the birth of new neurons) and synaptic plasticity, which are essential for forming new memories.

3. Human Correlation

The researchers confirmed that these findings are highly relevant to humans. They found that the severity of AD in human brain samples directly correlates with the degree of NAD+ disruption. Interestingly, "nondemented" individuals who had AD pathology (plaques) but remained cognitively intact (NDAN) showed gene expression patterns suggesting their brains had preserved NAD+ homeostasis naturally.

Actionable Implications for Everyday People

While P7C3-A20 is a research compound and not yet a prescribed medication, this study offers several vital insights for the general public:

• AD May Not Be a Death Sentence for Neurons (Early On): The study suggests that early cognitive impairment is driven by failing "resilience" (oxidative stress, inflammation, BBB leaks) rather than solely by fixed, permanent neuron loss. This means there is a window where the disease might be functionally reversed if resilience can be restored.

• The Importance of Metabolic Health: NAD+ is a "systemic metabolic currency". Lifestyle factors that support general metabolic health (such as exercise and proper nutrition) are known to influence the pathways that maintain cellular NAD+ levels.

• Biomarker Breakthroughs: The study identified p-tau217 as a sensitive blood biomarker that decreased when the mice recovered. This reinforces the potential for simple blood tests to not only diagnose AD but also to monitor if a treatment is actually working.

• A Shift in Hope: Perhaps the most significant takeaway is the shift in perspective. The "century-long dogma" that AD is irreversible is being scientifically challenged. This provides a mechanistic foundation for developing therapies aimed not just at slowing decline, but at achieving functional recovery.

Juvina Bioscience’s Cell Activator XR delivers purest NMN, a precursor to NAD+, in a perfectly dosed daily capsule. The delayed-release capsule technology releases the NMN right where your body can absorb it, ensuring bioavailability.

Source:

“Pharmacologic reversal of advanced Alzheimer’s disease in mice and identification of potential therapeutic nodes in human brain”, Chauby, K., Vázquez-Rosa E., Tripathi, S.J., Shin, M.K., et al. Cell Reports Medicine, 7(1), 2026. Link